Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Among authors: issa jj. Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3. Lancet Haematol. 2019. PMID: 31060979 Free PMC article. Clinical Trial.
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Issa JJ, et al. Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19. Lancet Oncol. 2015. PMID: 26296954 Free PMC article. Clinical Trial.
DNA Hypomethylating Drugs in Cancer Therapy.
Sato T, Issa JJ, Kropf P. Sato T, et al. Among authors: issa jj. Cold Spring Harb Perspect Med. 2017 May 1;7(5):a026948. doi: 10.1101/cshperspect.a026948. Cold Spring Harb Perspect Med. 2017. PMID: 28159832 Free PMC article. Review.
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Kantarjian HM, et al. Among authors: issa jj. Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24. Lancet Oncol. 2017. PMID: 28844816 Free PMC article. Clinical Trial.
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ. Roboz GJ, et al. Among authors: issa jj. Cancer. 2018 Jan 15;124(2):325-334. doi: 10.1002/cncr.31138. Epub 2017 Dec 6. Cancer. 2018. PMID: 29211308 Free PMC article. Clinical Trial.
Demethylator phenotypes in acute myeloid leukemia.
Kelly AD, Madzo J, Madireddi P, Kropf P, Good CR, Jelinek J, Issa JJ. Kelly AD, et al. Among authors: issa jj. Leukemia. 2018 Oct;32(10):2178-2188. doi: 10.1038/s41375-018-0084-2. Epub 2018 Mar 7. Leukemia. 2018. PMID: 29556023 Free PMC article.
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novák J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva L, Demeter J, Griffiths EA, Yee KWL, Issa JJ, Bewersdorf JP, Keer H, Hao Y, Azab M, Döhner H. Zeidan AM, et al. Among authors: issa jj. Blood. 2022 Jul 21;140(3):285-289. doi: 10.1182/blood.2022015832. Blood. 2022. PMID: 35507690 Free PMC article. No abstract available.
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Jang HJ, Hostetter G, Macfarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, Nichols PW, Chung W, Madzo J, Hahn NM, Quinn DI, Issa JJ, Topper MJ, Baylin SB, Shen H, Campbell KS, Jones PA, Plimack ER. Jang HJ, et al. Among authors: issa jj. Clin Cancer Res. 2023 Jun 1;29(11):2052-2065. doi: 10.1158/1078-0432.CCR-22-3642. Clin Cancer Res. 2023. PMID: 36928921 Free PMC article. Clinical Trial.
Transcriptional Selectivity of Epigenetic Therapy in Cancer.
Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, Okamoto Y, Zhang H, Chen X, Jelinek J, Issa JJ. Sato T, et al. Among authors: issa jj. Cancer Res. 2017 Jan 15;77(2):470-481. doi: 10.1158/0008-5472.CAN-16-0834. Epub 2016 Nov 22. Cancer Res. 2017. PMID: 27879268 Free PMC article.
43 results